Multimeric Anti-DR5 Antibody for Enhanced Binding Avidity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-DR5 monoclonal antibodies, such as Tigatuzumab, have limited clinical efficacy in treating cancers like bladder, gastric, ovarian, and non-small cell lung cancer, despite in vitro and in vivo effectiveness, highlighting the need for more effective therapies that can target DR5 with enhanced specificity and avidity.
Innovation Solution
A combination therapy involving dimeric or hexameric IgA or IgM antibodies that specifically and agonistically bind to DR5, administered with cancer therapies like radiation, platinum-based agents, or SMAC mimetics, to induce apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies like Tigatuzumab are used to target DR5, then DR5 binding is achieved, but clinical efficacy remains limited
Solution Approach 1:
The patent combines multiple antigen-binding domains (three to twelve) into a single multimeric antibody molecule, creating IgM or IgM-like antibodies that can simultaneously bind multiple DR5 receptors. This merging of binding functions increases binding avidity and enhances clinical efficacy compared to conventional monoclonal antibodies with single binding sites.
Solution Approach 2:
The invention creates composite antibody structures by assembling multiple antigen-binding domains with constant regions to form multimeric molecules. These composite structures possess both the specificity of individual binding domains and the enhanced avidity of multivalent configurations, resolving the contradiction between reliable DR5 targeting and sufficient binding strength.
2Device complexity
If conventional monoclonal antibodies are used, then simplicity of structure is maintained, but binding avidity to DR5 is insufficient
Solution Approach 1:
The antibody is segmented into multiple antigen-binding domains (three to twelve) that are distributed across the multimeric structure. Each domain can independently bind to DR5 receptors, and the segmentation allows the molecule to engage multiple receptors simultaneously, dramatically increasing binding avidity while maintaining a systematic organizational pattern.
Solution Approach 2:
The invention transitions from conventional monovalent or bivalent antibody structures to multivalent IgM or IgM-like structures with three to twelve binding domains. This dimensional expansion in binding valency creates a multimeric architecture that achieves high binding avidity through increased spatial engagement with multiple DR5 receptors on the cell surface.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively inhibits or delays malignant cell growth and induces apoptosis in cancer cells, offering improved therapeutic outcomes for difficult-to-treat tumors by enhancing the binding specificity and avidity to DR5 receptors.
Implementation Method 1
DR5 activation requires that at least three non-interacting receptor monomers be cross-linked, e.g., by a TRAIL ligand or agonist antibody, to form a stabilized receptor trimer, resulting in signal transduction across the cell membrane
Implementation Method 2
DR5 activation requires that at least three non-interacting receptor monomers be cross-linked, e.g., by a TRAIL ligand or agonist antibody, to form a stabilized receptor trimer
Implementation Method 3
The current standard of care for certain of these cancers includes radiation or chemotherapeutic agents that disrupt cellular growth and metabolism, e.g., by blocking DNA synthesis, blocking cell division, or promoting apoptosis
Data Source
AI summary
This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a taxane, a topoisomerase II inhibitor, a SMAC mimetic, a vinca alkaloid, a Brutons tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, a myeloid cell leukemia-1 (Mcl-1) inhibitor, or any combination thereof.